AGIOS PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | $20.00M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $12.90M | $-1.78 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | Before market open | – | – | – |
Press releases
Announcements Agios Pharmaceuticals filed with the SEC
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
J.P. Morgan Healthcare Conference 2026 Agios Pharmaceuticals Brian Goff, Chief Executive Officer 14 January 2026 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
Regulation FD disclosure · EX-99.1 to Form 8-K
Agios Pharmaceuticals Brian Goff, Chief Executive Officer January 15, 2025 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
Material agreement · Other events · EX-99.1 to Form 8-K
Agios Reports Business Highlights and First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
Regulation FD disclosure · EX-99.1 to Form 8-K
Agios Pharmaceuticals Brian Goff, Chief Executive Officer January 10, 2024 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Agios Reports Business Highlights and First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K